Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| German Federal Ministry of Education and Research | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The intervention study is designed to evaluate nutrient bioavailability and physiological impact of two selected microalgae species of interest in a randomized study in humans. The controlled study in parallel design will be conducted with healthy males and females between 20 and 35 years.
The microalgae are selected depending on their contents of long-chain omega-3 fatty acids, e.g. eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), high-quality protein (focus: essential amino acids), dietary fibers but also vitamin D pre-cursors and further vitamins, minerals and trace elements.The nutrient bioavailability is evaluated in a controlled, randomized, double-blind study in parallel design. The intervention products (smoothie enriched with Chlorella pyrenoidosa, Nannochloropsis salina) are consumed daily over 14 days. In addition, the background diet is standardised by provision of defined menu plans ensuring an optimal energy and nutrient intake. The control group I receive no intervention products and no menu plans and control group II receive a smoothie without microalage and defined menu plans.
A sup-group of five participants per group consume a test meal after the fasting blood sampling on the first study day. This is followed by a postprandial blood sampling after 30, 60, 90, 120 and 180 minutes.
The NovAL study is conducted to evaluate the bioavailability of nutrients such as omega-3 LC-PUFA, vitamin D, vitamin B12, further vitamins, amino acids, minerals, and trace elements from the selected microalgae species. Therefore, the concentration of these valuable nutrients and relevant markers of their status in humans (e.g. vitamin B12 status: holo-transcobalamin, methylmalonic acid, homocysteine; iron status: ferritin, transferrin, transferrin saturation) are analysed in the human biofluids (serum/plasma, erythrocytes, 24 h urine) before and after defined consumption of the selected microalgae species over 14 days. Besides the comprehensive analysis of the nutrient status in humans, cardiovascular risk factors and risk factors for diabetes mellitus type II are analysed. Thus, the NovAL study allows the assessment of i) the nutrient bioavailability from the selected microalgae species but also ii) their contribution on nutrient supply and prevention of non-communicable diseases such as cardiovascular diseases or diabetes mellitus type.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Microalgae I | Experimental | Smoothie (enriched with Chlorella pyrenoidosa) and standardised background diet (defined menu plans) |
|
| Microalgae II | Experimental | Smoothie (enriched with Nannochloropsis salina) and standardised background diet (defined menu plans) |
|
| Smoothie | Placebo Comparator | Smoothie (without microalgae) and standardised background diet (defined menu plans) |
|
| Control | No Intervention | no intervention (no smoothie, no menu plans) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Smoothie with microalgae | Dietary Supplement | Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae |
|
| Measure | Description | Time Frame |
|---|---|---|
| EPA concentration in plasma lipids | concentration of eicosapentaenoic acid (EPA) in % fatty acid methyl esthers (FAME) in plasma lipids | change from baseline after 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| blood lipids | total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides in mmol/l | change from baseline after 2 weeks |
| anthropometric data | body water, body fat, lean body mass, extracellular mass (ECM), body cell mass (BCM) in % |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Friedrich Schiller University | Jena | Thuringia | 07743 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
parallel design
Not provided
Not provided
It is not visible whether the smoothie is fortified with microalgae or not.
| change from baseline after 2 weeks |
| body mass index | body mass index (kg/m2) | change from baseline after 2 weeks |
| blood pressure | systolic blood pressure (mm Hg) diastolic blood pressure (mmHg) | change from baseline after 2 weeks |
| inflammation marker (blood) | high-sensitive c-reactive protein (mg/dl) | change from baseline after 2 weeks |
| homocysteine | homocysteine (µmol/l) | change from baseline after 2 weeks |
| holotranscobalamine | holotranscobalamine (pmol/l) | change from baseline after 2 weeks |
| glucose (fasting) | glucose (fasting) (mmol/l) | change from baseline after 2 weeks |
| insulin (fasting) | insulin (fasting) (mU/l) | change from baseline after 2 weeks |
| hemoglobin A1c (fasting) | hemoglobin A1c (fasting) (%) | change from baseline after 2 weeks |
| malodialdehyde modified LDL cholesterol | malodialdehyde modified LDL cholesterol (U/l) | change from baseline after 2 weeks |
| fatty acid distribution in plasma lipids | fatty acid distribution in plasma lipids in % FAME | change from baseline after 2 weeks |
| aspartate transaminase | aspartate transaminase (ASAT) in µmol/l*s | change from baseline after 2 weeks |
| alanine transaminase | alanine transaminase (ALAT) in µmol/l*s | change from baseline after 2 weeks |
| gamma-glutamyltransferase | gamma-glutamyltransferase (gGT) in µmol/l*s | change from baseline after 2 weeks |
| lactate dehydrogenase | lactate dehydrogenase (LDH) in µmol/l*s | change from baseline after 2 weeks |
| cholinesterase | cholinesterase in µmol/l*s | change from baseline after 2 weeks |
| kalium | kalium in mmol/l | change from baseline after 2 weeks |
| calcium | calcium in mmol/l | change from baseline after 2 weeks |
| transferrin | transferrin (g/l) | change from baseline after 2 weeks |
| ferritin | ferritin (µg/l) | change from baseline after 2 weeks |
| iron | iron (mg/dl) | change from baseline after 2 weeks |
| vitamin A | vitamin A (mmol/l) | change from baseline after 2 weeks |
| vitamin D | vitamin D (nmol/l) | change from baseline after 2 weeks |
| vitamin E | vitamin E (µmol/l) | change from baseline after 2 weeks |
| vitamin B1 | vitamin B1 (nmol/l) | change from baseline after 2 weeks |
| vitamin B6 | vitamin B6 (nmol/l) | change from baseline after 2 weeks |
| vitamin B12 | vitamin B12 (pmol/l) | change from baseline after 2 weeks |
| folic acid | folic acid (µg/l) | change from baseline after 2 weeks |
| vitamin B2 | vitamin B2 (µg/l) | change from baseline after 2 weeks |
| vitamin C | vitamin C (mg/l) | change from baseline after 2 weeks |
| vitamin H | vitamin H (ng/l) | change from baseline after 2 weeks |
| iodine (24 h urine) | iodine (µmol/l) | change from baseline after 2 weeks |
| selenium (24 h urine) | selenium (µmol/l) | change from baseline after 2 weeks |
| copper (24 h urine) | copper (µmol/l) | change from baseline after 2 weeks |
| zinc (24 h urine) | zinc (µmol/l) | change from baseline after 2 weeks |
| manganese (24 h urine) | manganese (nmol/l) | change from baseline after 2 weeks |
| natrium (24 h urine) | natrium (mmol/l) | change from baseline after 2 weeks |
| magnesium (24 h urine) | magnesium (mmol/l) | change from baseline after 2 weeks |
| creatinine (24 h urine) | creatinine (mmol/24 h) | change from baseline after 2 weeks |
| albumine (24 h urine) | albumine (mg/l) | change from baseline after 2 weeks |
| uric acid (24 h urine) | uric acid (mg/dl) | change from baseline after 2 weeks |